Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Urinary Tract Infection

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 62 articles:
HTML format



Single Articles


    August 2021
  1. BIRGY A, Madhi F, Jung C, Levy C, et al
    Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
    J Antimicrob Chemother. 2021 Aug 28. pii: 6359118. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  2. HENLY EL, Norris K, Rawson K, Zoulias N, et al
    Impact of long-term quorum sensing inhibition on uropathogenic Escherichia coli.
    J Antimicrob Chemother. 2021;76:909-919.
    PubMed     Abstract available


    February 2021
  3. ALEXANDRE K, Leysour de Rohello F, Dahyot S, Etienne M, et al
    Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study.
    J Antimicrob Chemother. 2021;76:784-788.
    PubMed     Abstract available


    January 2021
  4. BOEL JB, Antsupova V, Knudsen JD, Jarlov JO, et al
    Intravenous mecillinam compared with other beta-lactams as targeted treatment for Escherichia coli or Klebsiella spp. bacteraemia with urinary tract focus.
    J Antimicrob Chemother. 2021;76:206-211.
    PubMed     Abstract available


    December 2020
  5. LARRAMENDY S, Gaultier A, Fournier JP, Caillon J, et al
    Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study.
    J Antimicrob Chemother. 2020 Dec 22. pii: 6042378. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  6. STEWART AG, Harris PNA, Henderson A, Schembri MA, et al
    Erratum to: Oral cephalosporin and beta-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    J Antimicrob Chemother. 2020 Oct 28. pii: 5941854. doi: 10.1093.
    PubMed    


    August 2020
  7. RICHELSEN R, Smit J, Schonheyder HC, Laxsen Anru P, et al
    Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark.
    J Antimicrob Chemother. 2020 Aug 30. pii: 5899248. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  8. KUIPER SG, Dijkmans AC, Wilms EB, Kamerling IMC, et al
    Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.
    J Antimicrob Chemother. 2020 Jul 26. pii: 5876615. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  9. STEWART AG, Harris PNA, Henderson A, Schembri MA, et al
    Oral cephalosporin and beta-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    J Antimicrob Chemother. 2020 May 22. pii: 5842233. doi: 10.1093.
    PubMed     Abstract available


  10. PAGANO P, Marra A, Shinabarger D, Pillar C, et al
    In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium.
    J Antimicrob Chemother. 2020 May 19. pii: 5840661. doi: 10.1093.
    PubMed     Abstract available


  11. MARTINEZ EP, van Rosmalen J, Bustillos R, Natsch S, et al
    Trends, seasonality and the association between outpatient antibiotic use and antimicrobial resistance among urinary bacteria in the Netherlands.
    J Antimicrob Chemother. 2020 May 17. pii: 5838345. doi: 10.1093.
    PubMed     Abstract available


  12. CHANAME PINEDO LE, Bruyndonckx R, Catry B, Latour K, et al
    Fluoroquinolone resistance in Escherichia coli isolates after exposure to non-fluoroquinolone antibiotics: a retrospective case-control study.
    J Antimicrob Chemother. 2020 May 12. pii: 5836063. doi: 10.1093.
    PubMed     Abstract available


  13. ABBOTT IJ, van Gorp E, Wijma RA, Dekker J, et al
    Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
    J Antimicrob Chemother. 2020 May 3. pii: 5828355. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  14. HATLEN TJ, Flor R, Nguyen MH, Lee GH, et al
    Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system.
    J Antimicrob Chemother. 2020 Apr 17. pii: 5821485. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  15. FINDLAY J, Gould VC, North P, Bowker KE, et al
    Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.
    J Antimicrob Chemother. 2020;75:65-71.
    PubMed     Abstract available


    December 2019
  16. ABBOTT IJ, Dekker J, van Gorp E, Wijma RA, et al
    Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
    J Antimicrob Chemother. 2019 Dec 24. pii: 5686404. doi: 10.1093.
    PubMed     Abstract available


  17. NUSSBAUMER-PROLL AK, Eberl S, Reiter B, Stimpfl T, et al
    Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections.
    J Antimicrob Chemother. 2019 Dec 3. pii: 5651068. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  18. BIRGY A, Madhi F, Jung C, Levy C, et al
    Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017.
    J Antimicrob Chemother. 2019 Oct 16. pii: 5588579. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  19. BOEL JB, Jansaker F, Hertz FB, Hansen KH, et al
    Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study.
    J Antimicrob Chemother. 2019 May 16. pii: 5490639. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  20. GRAHAM M, Walker DA, Haremza E, Morris AJ, et al
    RCPAQAP audit of antimicrobial reporting in Australian and New Zealand laboratories: opportunities for laboratory contribution to antimicrobial stewardship.
    J Antimicrob Chemother. 2019;74:251-255.
    PubMed     Abstract available


  21. BELAS A, Marques C, Aboim C, Pomba C, et al
    Emergence of Escherichia coli ST131 H30/H30-Rx subclones in companion animals.
    J Antimicrob Chemother. 2019;74:266-269.
    PubMed    


    December 2018
  22. CROKER R, Walker AJ, Goldacre B
    Why did some practices not implement new antibiotic prescribing guidelines on urinary tract infection? A cohort study and survey in NHS England primary care.
    J Antimicrob Chemother. 2018 Dec 22. pii: 5258046. doi: 10.1093.
    PubMed     Abstract available


  23. MARQUES C, Menezes J, Belas A, Aboim C, et al
    Klebsiella pneumoniae causing urinary tract infections in companion animals and humans: population structure, antimicrobial resistance and virulence genes.
    J Antimicrob Chemother. 2018 Dec 10. pii: 5237779. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  24. PULCINI C, Clerc-Urmes I, Attinsounon CA, Fougnot S, et al
    Antibiotic resistance of Enterobacteriaceae causing urinary tract infections in elderly patients living in the community and in the nursing home: a retrospective observational study.
    J Antimicrob Chemother. 2018 Nov 30. pii: 5224777. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  25. BROSH-NISSIMOV T, Navon-Venezia S, Keller N, Amit S, et al
    Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults.
    J Antimicrob Chemother. 2018 Oct 23. pii: 5144000. doi: 10.1093.
    PubMed     Abstract available


  26. O'GRADY MC, Barry L, Corcoran GD, Hooton C, et al
    Empirical treatment of urinary tract infections: how rational are our guidelines?
    J Antimicrob Chemother. 2018 Oct 8. pii: 5123549. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  27. HOWARD JC, Anderson T, Creighton J, Freeman JT, et al
    Geographical and temporal clustering of OXA-48-producing Escherichia coli ST410 causing community-onset urinary tract infection in Christchurch, New Zealand.
    J Antimicrob Chemother. 2018 Jul 3. pii: 5048317. doi: 10.1093.
    PubMed    


    June 2018
  28. BOLLESTAD M, Grude N, Solhaug S, Raffelsberger N, et al
    Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
    J Antimicrob Chemother. 2018 Jun 29. pii: 5046991. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  29. NYGAARD JENSEN J, Melander E, Hedin K, Bjerrum L, et al
    Comparison of antibiotic prescribing and antimicrobial resistance in urinary tract infections at the municipal level among women in two Nordic regions.
    J Antimicrob Chemother. 2018 May 10. pii: 4995081. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  30. ALEXANDRE K, Reveillon-Istin M, Fabre R, Delbos V, et al
    Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods.
    J Antimicrob Chemother. 2018 Apr 6. pii: 4964016. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  31. AN J, Lai K, Ma Y, Guo L, et al
    Emergence of multiple carbapenemase-producing organisms in single patients: an increasing threat to treatment of infection.
    J Antimicrob Chemother. 2018;73:544-546.
    PubMed    


    January 2018
  32. POUWELS KB, Freeman R, Muller-Pebody B, Rooney G, et al
    Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association.
    J Antimicrob Chemother. 2018 Jan 31. pii: 4832009. doi: 10.1093.
    PubMed     Abstract available


  33. BRYCE A, Costelloe C, Wootton M, Butler CC, et al
    Comparison of risk factors for, and prevalence of, antibiotic resistance in contaminating and pathogenic urinary Escherichia coli in children in primary care: prospective cohort study.
    J Antimicrob Chemother. 2018 Jan 29. pii: 4828185. doi: 10.1093.
    PubMed     Abstract available


  34. ROZANSKA A, Pac A, Romanik M, Bulanda M, et al
    Outpatient post-partum antibiotic prescription: method of identification of infection control areas demanding improvements and verification of sensitivity of infection registration.
    J Antimicrob Chemother. 2018;73:240-245.
    PubMed     Abstract available


  35. MALCOLM W, Fletcher E, Kavanagh K, Deshpande A, et al
    Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland Infection Intelligence Platform.
    J Antimicrob Chemother. 2018;73:223-230.
    PubMed     Abstract available


    November 2017
  36. MARQUES C, Belas A, Franco A, Aboim C, et al
    Increase in antimicrobial resistance and emergence of major international high-risk clonal lineages in dogs and cats with urinary tract infection: 16 year retrospective study.
    J Antimicrob Chemother. 2017 Nov 9. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  37. FRANSEN F, Melchers MJB, Lagarde CMC, Meletiadis J, et al
    Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections.
    J Antimicrob Chemother. 2017 Sep 11. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  38. SIMS M, Mariyanovski V, McLeroth P, Akers W, et al
    Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Abstract available


  39. SHALLCROSS L, Beckley N, Rait G, Hayward A, et al
    Antibiotic prescribing frequency amongst patients in primary care: a cohort study using electronic health records.
    J Antimicrob Chemother. 2017;72:1818-1824.
    PubMed     Abstract available


    May 2017
  40. PFALLER MA, Bassetti M, Duncan LR, Castanheira M, et al
    Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    J Antimicrob Chemother. 2017;72:1386-1395.
    PubMed     Abstract available


    January 2017
  41. SUGIANLI AK, Ginting F, Kusumawati RL, Pranggono EH, et al
    Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia.
    J Antimicrob Chemother. 2017 Jan 30. pii: dkw578. doi: 10.1093.
    PubMed     Abstract available


  42. KOKSAL I, Yilmaz G, Unal S, Zarakolu P, et al
    Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
    J Antimicrob Chemother. 2017 Jan 25. pii: dkw574. doi: 10.1093.
    PubMed     Abstract available


  43. STONE GG, Bradford PA, Yates K, Newell P, et al
    In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    J Antimicrob Chemother. 2017 Jan 14. pii: dkw561. doi: 10.1093.
    PubMed     Abstract available


  44. ROSELLO A, Hayward AC, Hopkins S, Horner C, et al
    Impact of long-term care facility residence on the antibiotic resistance of urinary tract Escherichia coli and Klebsiella.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw555. doi: 10.1093.
    PubMed     Abstract available


  45. POPEJOY MW, Paterson DL, Cloutier D, Huntington JA, et al
    Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    J Antimicrob Chemother. 2017;72:268-272.
    PubMed     Abstract available


    December 2016
  46. STALEY C, Vaughn BP, Graiziger CT, Sadowsky MJ, et al
    Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw499. doi: 10.1093.
    PubMed     Abstract available


  47. KULLAR R, Wagenlehner FM, Popejoy MW, Long J, et al
    Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw486. doi: 10.1093.
    PubMed     Abstract available


    October 2016
  48. JEAN SS, Hsueh PR
    Distribution of ESBLs, AmpC beta-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial Resist
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    September 2016
  49. SCHMIDT K, Mwaigwisya S, Crossman LC, Doumith M, et al
    Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


  50. MULDER M, Kiefte-de Jong JC, Goessens WH, de Visser H, et al
    Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    August 2016
  51. DELISLE G, Quach C, Domingo MC, Boudreault AA, et al
    Escherichia coli antimicrobial susceptibility profile and cumulative antibiogram to guide empirical treatment of uncomplicated urinary tract infections in women in the province of Quebec, 2010-15.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    June 2016
  52. CHIN TL, McNulty C, Beck C, MacGowan A, et al
    Antimicrobial resistance surveillance in urinary tract infections in primary care.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


  53. FRANSEN F, Melchers MJ, Meletiadis J, Mouton JW, et al
    Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    May 2016
  54. SEROY JT, Grim SA, Reid GE, Wellington T, et al
    Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


  55. FREIRE MP, de Oliveira Garcia D, Cury AP, Spadao F, et al
    Outbreak of IMP-producing carbapenem-resistant Enterobacter gergoviae among kidney transplant recipients.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    March 2016
  56. HUNTINGTON JA, Sakoulas G, Umeh O, Cloutier DJ, et al
    Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available


    August 2015
  57. NOMAMIUKOR BO, Horner C, Kirby A, Hughes GJ, et al
    Living conditions are associated with increased antibiotic resistance in community isolates of Escherichia coli.
    J Antimicrob Chemother. 2015.
    PubMed     Abstract available


    July 2015
  58. ALGHORIBI MF, Gibreel TM, Farnham G, Al Johani SM, et al
    Antibiotic-resistant ST38, ST131 and ST405 strains are the leading uropathogenic Escherichia coli clones in Riyadh, Saudi Arabia.
    J Antimicrob Chemother. 2015.
    PubMed     Abstract available


  59. VERVOORT J, Xavier BB, Stewardson A, Coenen S, et al
    Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota.
    J Antimicrob Chemother. 2015;70:1989-92.
    PubMed     Abstract available


    April 2015
  60. KOMP LINDGREN P, Klockars O, Malmberg C, Cars O, et al
    Pharmacodynamic studies of nitrofurantoin against common uropathogens.
    J Antimicrob Chemother. 2015;70:1076-82.
    PubMed     Abstract available


    March 2015
  61. CHIN TL, MacGowan AP, Bowker KE, Elder F, et al
    Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England.
    J Antimicrob Chemother. 2015.
    PubMed    


  62. IRONMONGER D, Edeghere O, Bains A, Loy R, et al
    Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years.
    J Antimicrob Chemother. 2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Urinary Tract Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: